JOHNSON & JOHNSON 8K

Johnson & Johnson entered into a strategic collaboration and option-to-acquire agreement with Sail Biomedicines to develop in vivo CAR‑T therapies, involving substantial upfront, milestone, equity, and potential acquisition payments with projected EPS dilution.

On July 29, 2026, Johnson & Johnson announced that it entered into strategic agreements and a collaboration with Sail Biomedicines to jointly develop Sail’s in vivo CAR-T platform for immune-mediated diseases, including a $785 million package of initial payments (comprised of a $465 million equity investment and additional upfront/near-term consideration), potential contingent development milestone payments of $140 million, and the granting to Johnson & Johnson of an exclusive option to acquire Sail for $2.58 billion, a transaction that is expected, assuming option exercise, to dilute Johnson & Johnson’s adjusted operational EPS by approximately $0.18 in 2026 and $1.28 in 2027, subject to regulatory approvals and other conditions.

Filing Facts

CIK

200406

Ticker

JNJ

Form

8K

Source Type

fda

Accession

0000200406-26-000163

Alert Tier

8